Report for Q1 2026
Filed with SSE · · 15 pages · Chinese
Mabwell (Shanghai) Bioscience Co., Ltd. on 6ix
Earlier from Mabwell (Shanghai) Bioscience
- Announcement on the Public Offering Price of Overseas Listed Foreign Shares (H-shares)
- Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer
- 2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations
- Case Report of Mabwell's Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
- Mabwell Passes On-site GMP Inspection by Regulatory Authority of PIC/S Member Country (Jordan) for the First Time
Later from Mabwell (Shanghai) Bioscience
- 2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- World's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application
- Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection)
- Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
Follow Mabwell (Shanghai) Bioscience into a list and get an email when it puts out news.
Follow Mabwell (Shanghai) Bioscience